This paper is in the following e-collection/theme issue:

RCTs - Pilots/Feasibility Studies (non-eHealth) (32) Imaging Informatics (193) Medical imaging (28)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/46709, first published .
Efficacy and Safety of the Natural Killer T Cell–Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial

Efficacy and Safety of the Natural Killer T Cell–Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial

Efficacy and Safety of the Natural Killer T Cell–Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial

Authors of this article:

Tomoko Okamoto1 Author Orcid Image ;   Takami Ishizuka2 Author Orcid Image ;   Reiko Shimizu2 Author Orcid Image ;   Yasuko Asahina2 Author Orcid Image ;   Harumasa Nakamura2 Author Orcid Image ;   Yuko Shimizu3 Author Orcid Image ;   Yoichiro Nishida4 Author Orcid Image ;   Takanori Yokota4 Author Orcid Image ;   Youwei Lin1, 5 Author Orcid Image ;   Wakiro Sato5 Author Orcid Image ;   Takashi Yamamura5 Author Orcid Image
Article Authors Cited by Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.